Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options

Joachim Jankowski, Jürgen Floege, Danilo Fliser, Michael Böhm, Nikolaus Marx, Joachim Jankowski, Jürgen Floege, Danilo Fliser, Michael Böhm, Nikolaus Marx

Abstract

Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. Although the incidence and prevalence of cardiovascular events is already significantly higher in patients with early CKD stages (CKD stages 1-3) compared with the general population, patients with advanced CKD stages (CKD stages 4-5) exhibit a markedly elevated risk. Cardiovascular rather than end-stage kidney disease (CKD stage 5) is the leading cause of death in this high-risk population. CKD causes a systemic, chronic proinflammatory state contributing to vascular and myocardial remodeling processes resulting in atherosclerotic lesions, vascular calcification, and vascular senescence as well as myocardial fibrosis and calcification of cardiac valves. In this respect, CKD mimics an accelerated aging of the cardiovascular system. This overview article summarizes the current understanding and clinical consequences of cardiovascular disease in CKD.

Keywords: arrhythmias; cardiovascular disease; chronic kidney disease; clinical aspects; death; heart failure; sudden cardiac.

Figures

Figure 1.
Figure 1.
Cardiovascular mortality in the general population and in patients with end-stage kidney disease. In 25- to 34-year-old patients with end-stage kidney disease, annual mortality is increased 500- to 1000-fold and corresponds to that of the ≈85-year-old general population. Adapted from Foley et al.
Figure 2.
Figure 2.
Interaction of cardiovascular disease (CVD) and chronic kidney disease (CKD). Various mediators and mechanisms in vascular disease, heart failure, and CKD contribute to the progression of CVD and influence the prognosis of patients. PTM indicates post-translational modification.
Figure 3.
Figure 3.
Classification and prognosis of chronic kidney disease (CKD) from 2012 KDIGO (Kidney Disease Improving Global Outcomes) guidelines. GFR indicates glomerular filtration rate. Adapted from the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.
Figure 4.
Figure 4.
Annual incidence rates of end-stage kidney disease in different countries. Adapted from Jha et al.
Figure 5.
Figure 5.
Independent association of kidney function with cardiovascular mortality. ACR indicates albumin-to-creatinine ratio; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; and HR, hazard ratio. Adapted and modified from Gansevoort et al.
Figure 6.
Figure 6.
Independent association of kidney function with cardiovascular mortality. ACR, albumin-to-creatinine ratio; and eGFR, estimated glomerular filtration rate. Adapted and modified from Gansevoort et al.
Figure 7.
Figure 7.
Cause-specific mortality according to varying levels of kidney dysfunction. For the 3 categories of kidney dysfunction, cause-specific mortality is depicted. Sudden cardiac death was the major cause of death in patients with end-stage renal disease (ESRD) on dialysis (50.0% vs 10.1% [glomerular filtration rate {GFR} <60 mL/min] vs 10.3% [GFR ≥60 mL/min], χ2P=0.010). Number at the top of each bar is the mortality rate; number within the bar is the n per group. The unknown category was reserved for those patients whose cause of death could not be determined. Adapted from Cheema et al.

References

    1. Bright R. Cases and observations, illustrative of renal disease, accompanied with the secretion of albuminous urine. Guy’s Hosp Trans. 1836338–379
    1. Stevens PE, O’Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, Hague N, New J, Farmer CK. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72:92–99. doi: 10.1038/sj.ki.5002273
    1. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M; Alberta Kidney Disease Network. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26:2504–2511. doi: 10.1681/ASN.2014070714
    1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238–1252. doi: 10.1016/S0140-6736(16)32064-5
    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;325 suppl 3S112–S119. doi: 10.1053/ajkd.1998.v32.pm9820470
    1. Vanholder R, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, et al. . Uremic toxicity: present state of the art. Int J Artif Organs. 2001;24:695–725. doi: 10.1177/039139880102401004
    1. Kuo IY, Chapman AB. Polycystins, ADPKD, and cardiovascular disease. Kidney Int Rep. 2020;5:396–406. doi: 10.1016/j.ekir.2019.12.007
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266
    1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100. doi: 10.1111/j.1523-1755.2005.00365.x
    1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147. doi: 10.7326/0003-4819-139-2-200307150-00013
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. doi: 10.1038/kisup.2012.76
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Chapter 1: definition and classification of CKD. Kidney Int Suppl (2011). 2013;3:19–62. doi: 10.1038/kisup.2012.64
    1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–2081. doi: 10.1016/S0140-6736(10)60674-5
    1. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969–975. doi: 10.1161/CIRCULATIONAHA.105.538132
    1. Mulè G, Castiglia A, Cusumano C, Scaduto E, Geraci G, Altieri D, Di Natale E, Cacciatore O, Cerasola G, Cottone S. Subclinical kidney damage in hypertensive patients: a renal window opened on the cardiovascular system. Focus on microalbuminuria. Adv Exp Med Biol. 2017;956:279–306. doi: 10.1007/5584_2016_85
    1. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28. doi: 10.1038/ki.2010.483
    1. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, Levin A. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158–169. doi: 10.1016/S0140-6736(13)60439-0
    1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11:e0158765. doi: 10.1371/journal.pone.0158765
    1. International Society of Nephrology. ISN Global Health Atlas. 2019. Accessed February 25, 2021.
    1. United States Renal Data System, Annual Data Report. 2018. Accessed February 25, 2021.
    1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–272. doi: 10.1016/S0140-6736(13)60687-X
    1. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12:73–81. doi: 10.1038/nrneph.2015.173
    1. Ma I, Guo M, Muruve D, Benediktsson H, Naugler C. Sociodemographic associations with abnormal estimated glomerular filtration rate (eGFR) in a large Canadian city: a cross-sectional observation study. BMC Nephrol. 2018;19:198. doi: 10.1186/s12882-018-0991-5
    1. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12:1713–1720
    1. Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23:19–28. doi: 10.1053/j.ackd.2015.08.004
    1. Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014;11:525–535. doi: 10.2217/cpr.14.46
    1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034–2047. doi: 10.1681/ASN.2005101085
    1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81. doi: 10.1016/S0140-6736(10)60674-5
    1. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, van der Velde M, Matsushita K, et al. ; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–1352. doi: 10.1038/ki.2010.536
    1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–352. doi: 10.1016/S0140-6736(13)60595-4
    1. Buglioni A, Burnett JC., Jr. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta. 2015;443:3–8. doi: 10.1016/j.cca.2014.10.027
    1. Briet M, Barhoumi T, Mian MO, Sierra C, Boutouyrie P, Davidman M, Bercovitch D, Nessim SJ, Frisch G, Paradis P, et al. . Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc. 2013;2:e000128. doi: 10.1161/JAHA.113.000128
    1. Onal EM, Sag AA, Sal O, Yerlikaya A, Afsar B, Kanbay M. Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension. Clin Exp Hypertens. 2017;39:197–209. doi: 10.1080/10641963.2016.1246565
    1. Nasrallah R, Hassouneh R, Hébert RL. PGE2, kidney disease, and cardiovascular risk: beyond hypertension and diabetes. J Am Soc Nephrol. 2016;27:666–676. doi: 10.1681/ASN.2015050528
    1. Tan K, Sethi SK. Biomarkers in cardiorenal syndromes. Transl Res. 2014;164:122–134. doi: 10.1016/j.trsl.2014.04.011
    1. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4:1201–1228. doi: 10.1002/cphy.c130040
    1. Agharazii M, St-Louis R, Gautier-Bastien A, Ung RV, Mokas S, Larivière R, Richard DE. Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification. Am J Hypertens. 2015;28:746–755. doi: 10.1093/ajh/hpu225
    1. Fujii H, Goto S, Fukagawa M. Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins. 2018;10:202–220. doi: 10.3390/toxins10050202
    1. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, et al. ; Board of the EURECA-m Working Group of ERA-EDTA. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383:1831–1843. doi: 10.1016/S0140-6736(14)60384-6
    1. Major RW, Cheng MRI, Grant RA, Shantikumar S, Xu G, Oozeerally I, Brunskill NJ, Gray LJ. Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS One. 2018;13:e0192895. doi: 10.1371/journal.pone.0192895
    1. Roehm B, Weiner DE. Blood pressure targets and kidney and cardiovascular disease: same data but discordant guidelines. Curr Opin Nephrol Hypertens. 2019;28:245–250. doi: 10.1097/MNH.0000000000000492
    1. Zewinger S, Kleber ME, Rohrer L, Lehmann M, Triem S, Jennings RT, Petrakis I, Dressel A, Lepper PM, Scharnagl H, et al. . Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur Heart J. 2017;38:1597–1607. doi: 10.1093/eurheartj/ehx118
    1. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. ; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. doi: 10.1056/NEJMoa0802987
    1. Ter Braake AD, Shanahan CM, de Baaij JHF. Magnesium counteracts vascular calcification: passive interference or active modulation? Arterioscler Thromb Vasc Biol. 2017;37:1431–1445. doi: 10.1161/ATVBAHA.117.309182
    1. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, Steppan S, Volsek M, Kribben A, Nierhaus M, et al. . Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol. 2012;35:31–39. doi: 10.1159/000334742
    1. Brandenburg VM, Reinartz S, Kaesler N, Krüger T, Dirrichs T, Kramann R, Peeters F, Floege J, Keszei A, Marx N, et al. . Slower progress of aortic valve calcification with vitamin K supplementation: results from a prospective interventional proof-of-concept study. Circulation. 2017;135:2081–2083. doi: 10.1161/CIRCULATIONAHA.116.027011
    1. Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, Thuren T, Cornel JH. Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018;71:2405–2414. doi: 10.1016/j.jacc.2018.03.490
    1. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. 2016. Accessed February 25, 2021.
    1. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847. doi: 10.1161/01.cir.97.18.1837
    1. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet, 2017. 2017. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention
    1. Matsushita K, Kwak L, Ballew SH, Grams ME, Selvin E, Folsom AR, Coresh J, Tang W. Chronic kidney disease measures and the risk of abdominal aortic aneurysm. Atherosclerosis. 2018;279:107–113. doi: 10.1016/j.atherosclerosis.2018.08.043
    1. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50:217–224. doi: 10.1016/j.jacc.2007.03.037
    1. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:844–846. doi: 10.1161/CIRCULATIONAHA.110.960138
    1. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139. doi: 10.1056/NEJMoa0808431
    1. Maini R, Wong DB, Addison D, Chiang E, Weisbord SD, Jneid H. Persistent underrepresentation of kidney disease in randomized, controlled trials of cardiovascular disease in the contemporary era. J Am Soc Nephrol. 2018;29:2782–2786. doi: 10.1681/ASN.2018070674
    1. Shroff R, Speer T, Colin S, Charakida M, Zewinger S, Staels B, Chinetti-Gbaguidi G, Hettrich I, Rohrer L, O’Neill F, et al. . HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol. 2014;25:2658–2668. doi: 10.1681/ASN.2013111212
    1. Brunet P, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, Dignat-George F, Jourde-Chiche N, Argiles A, Burtey S. Does uremia cause vascular dysfunction? Kidney Blood Press Res. 2011;34:284–290. doi: 10.1159/000327131
    1. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, et al. . Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483. doi: 10.1056/NEJM200005183422003
    1. O’Neill WC, Lomashvili KA. Recent progress in the treatment of vascular calcification. Kidney Int. 2010;78:1232–1239. doi: 10.1038/ki.2010.334
    1. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–1021. doi: 10.1093/ndt/15.7.1014
    1. London GM, Guerin AP. Influence of arterial pulse and reflected waves on blood pressure and cardiac function. Am Heart J. 1999;1383 pt 2220–224. doi: 10.1016/s0002-8703(99)70313-3
    1. Gauthier-Bastien A, Ung RV, Larivière R, Mac-Way F, Lebel M, Agharazii M. Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease. Clin Exp Hypertens. 2014;36:173–180. doi: 10.3109/10641963.2013.804541
    1. Shetty M, Chowdhury Y, Yegneswaran B. Calcific uremic arteriolopathy. Cleve Clin J Med. 2018;85:584–585. doi: 10.3949/ccjm.85a.18009
    1. Brandenburg VM, Evenepoel P, Floege J, Goldsmith D, Kramann R, Massy Z, Mazzaferro S, Schurgers LJ, Sinha S, Torregrosa V, et al. ; ERA-EDTA Working Group on CKD-MBD and EUCALNET. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrol Dial Transplant. 2016;31:1211–1219. doi: 10.1093/ndt/gfw025
    1. Shaker JL, Deftos L. Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A, Hershman JM, Hofland J, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Purnell J, Singer F, Stratakis CA, Trence DL, Wilson DP, eds. Calcium and Phosphate Homeostasis. 2018 Jan 19. In: Endotext [Internet]. 2000–. South Dartmouth (MA): , Inc.
    1. Ellis CL, O’Neill WC. Questionable specificity of histologic findings in calcific uremic arteriolopathy. Kidney Int. 2018;94:390–395. doi: 10.1016/j.kint.2018.03.016
    1. Shobeiri N, Pang J, Adams MA, Holden RM. Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. J Hypertens. 2013;31:160–168. doi: 10.1097/HJH.0b013e32835b15bb
    1. Raggi P. Cardiovascular disease: coronary artery calcification predicts risk of CVD in patients with CKD. Nat Rev Nephrol. 2017;13:324–326. doi: 10.1038/nrneph.2017.61
    1. De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie Study. J Am Soc Nephrol. 2020;31:186–196. doi: 10.1681/ASN.2019060579
    1. Floege J. Magnesium in CKD: more than a calcification inhibitor? J Nephrol. 2015;28:269–277. doi: 10.1007/s40620-014-0140-6
    1. Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purif. 2017;43:179–188. doi: 10.1159/000452725
    1. Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S, Matsui I, Hashimoto N, Matsumoto A, Shimada K, et al. . A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol. 2019;30:1073–1085. doi: 10.1681/ASN.2018111150
    1. Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, et al. ; European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association – European Dialysis Transplantation Association (ERA-EDTA). The systemic nature of CKD. Nat Rev Nephrol. 2017;13:344–358. doi: 10.1038/nrneph.2017.52
    1. Amdur RL, Feldman HI, Dominic EA, Anderson AH, Beddhu S, Rahman M, Wolf M, Reilly M, Ojo A, Townsend RR, et al. ; CRIC Study Investigators. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC Study. Am J Kidney Dis. 2019;73:344–353. doi: 10.1053/j.ajkd.2018.09.012
    1. Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Perthel R, Lovric S, Lichtinghagen R, Kliem V, Bode-Böger SM. Unilateral nephrectomy causes an abrupt increase in inflammatory mediators and a simultaneous decrease in plasma ADMA: a study in living kidney donors. Am J Physiol Renal Physiol. 2011;301:F1042–F1046. doi: 10.1152/ajprenal.00640.2010
    1. Alhaj E, Alhaj N, Rahman I, Niazi TO, Berkowitz R, Klapholz M. Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Fail. 2013;19:E40–E45. doi: 10.1111/chf.12030
    1. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 20094 suppl 1S79–S91. doi: 10.2215/CJN.04860709
    1. Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 2015;5:254–266. doi: 10.1159/000435838
    1. Little WC. Heart failure with a normal left ventricular ejection fraction: diastolic heart failure. Trans Am Clin Climatol Assoc. 2008;119:93–99. discussion 99
    1. Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:937398. doi: 10.1155/2014/937398
    1. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, et al. ; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791. doi: 10.1093/eurheartj/ehx391
    1. Wang Z, Jiang A, Wei F, Chen H. Cardiac valve calcification and risk of cardiovascular or all-cause mortality in dialysis patients: a meta-analysis. BMC Cardiovasc Disord. 2018;18:12. doi: 10.1186/s12872-018-0747-y
    1. Abd Alamir M, Radulescu V, Goyfman M, Mohler ER, III, Gao YL, Budoff MJ; CRIC Study Investigators. Prevalence and correlates of mitral annular calcification in adults with chronic kidney disease: results from CRIC study. Atherosclerosis. 2015;242:117–122. doi: 10.1016/j.atherosclerosis.2015.07.013
    1. Rong S, Qiu X, Jin X, Shang M, Huang Y, Tang Z, Yuan W. Risk factors for heart valve calcification in chronic kidney disease. Medicine (Baltimore). 2018;97:e9804. doi: 10.1097/MD.0000000000009804
    1. Urena-Torres P, D’Marco L, Raggi P, Garcia-Moll X, Brandenburg V, Mazzaferro S, Lieber A, Guirado L, Bover J. Valvular heart disease and calcification in CKD: more common than appreciated. Nephrol Dial Transplant. 2019;1:1–8
    1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. ; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104. doi: 10.1093/eurheartj/ehy339
    1. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, et al. ; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–2192. doi: 10.1016/S0140-6736(11)60739-3
    1. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, et al. ; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–2192. doi: 10.1016/S0140-6736(11)60739-3
    1. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248. doi: 10.1056/NEJMoa043545
    1. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-RiskaAURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–1407. doi: 10.1056/NEJMoa0810177
    1. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263–275. doi: 10.7326/0003-4819-157-4-201208210-00007
    1. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Copetti M, Graziano G, Tognoni G, Jardine M, et al. . Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156:445–459. doi: 10.7326/0003-4819-156-6-201203200-00007
    1. Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C, Kaul U, Reynolds HR, Mazurek T, Sidhu MS, et al. ; ISCHEMIA-CKD Research Group. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020;382:1608–1618. doi: 10.1056/NEJMoa1915925
    1. Spertus JA, Jones PG, Maron DJ, Mark DB, O’Brien SM, Fleg JL, Reynolds HR, Stone GW, Sidhu MS, Chaitman BR, et al. ; ISCHEMIA-CKD Research Group. Health status after invasive or conservative care in coronary and advanced kidney disease. N Engl J Med. 2020;382:1619–1628. doi: 10.1056/NEJMoa1916374
    1. Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK, Mega JL, Menon V, Page RL, II, Newby LK; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Functional Genomics and Translational Biology, Council on the Kidney in Cardiovascular Disease, and Council on Quality of Care and Outcomes Research. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131:1123–1149. doi: 10.1161/CIR.0000000000000183
    1. Edner M, Benson L, Dahlström U, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J. 2015;36:2318–2326. doi: 10.1093/eurheartj/ehv268
    1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355. doi: 10.1056/NEJM199605233342101
    1. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–2318. doi: 10.1161/01.cir.100.23.2312
    1. Packer M, Miller AB. Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure. Am J Cardiol. 1999;84:1L–2L. doi: 10.1016/s0002-9149(99)00358-6
    1. Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, Krum H, Tonkin A, Perkovic V. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:1152–1161. doi: 10.1016/j.jacc.2011.04.041
    1. Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Böhm M, McMurray JJV, Wikstrand J, Anker SD, et al. ; Beta-Blockers in Heart Failure Collaborative Group. Impact of renal impairment on beta-blocker efficacy in patients with heart failure. J Am Coll Cardiol. 2019;74:2893–2904. doi: 10.1016/j.jacc.2019.09.059
    1. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21. doi: 10.1056/NEJMoa1009492
    1. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528–536. doi: 10.1016/j.jacc.2013.09.056
    1. Charytan DM, Himmelfarb J, Ikizler TA, Raj DS, Hsu JY, Landis JR, Anderson AH, Hung AM, Mehrotra R, Sharma S, et al. ; Hemodialysis Novel Therapies Consortium. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int. 2019;95:973–982. doi: 10.1016/j.kint.2018.08.034
    1. Hammer F, Malzahn U, Donhauser J, Betz C, Schneider MP, Grupp C, Pollak N, Störk S, Wanner C, Krane V; MiREnDa Study Group. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int. 2019;95:983–991. doi: 10.1016/j.kint.2018.11.025
    1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. ; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi: 10.1056/NEJMoa1409077
    1. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885. doi: 10.1016/S0140-6736(10)61198-1
    1. Voors AA, van Veldhuisen DJ, Robertson M, Ford I, Borer JS, Böhm M, Komajda M, Swedberg K, Tavazzi L; SHIFT investigators. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail. 2014;16:426–434. doi: 10.1002/ejhf.59
    1. Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, et al. . Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14:727–749. doi: 10.1038/s41581-018-0072-9
    1. Genovesi S, Boriani G, Covic A, Vernooij RWM, Combe C, Burlacu A, Davenport A, Kanbay M, Kirmizis D, Schneditz D, et al. . Sudden cardiac death in dialysis patients: different causes and management strategies. Nephrol Dial Transplant. 2019;1:1–10. doi: 10.1093/ndt/gfz182
    1. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373:1289–1300. doi: 10.1016/S0140-6736(09)60256-7
    1. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, et al. . Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533–1541. doi: 10.1161/CIRCULATIONAHA.108.840827
    1. Green D, Roberts PR, New DI, Kalra PA. Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis. 2011;57:921–929. doi: 10.1053/j.ajkd.2011.02.376
    1. Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G. Characteristics of sudden death in hemodialysis patients. Kidney Int. 2006;69:2268–2273. doi: 10.1038/sj.ki.5000446
    1. Cheema A, Singh T, Kanwar M, Chilukuri K, Maria V, Saleem F, Johnson K, Frank J, Pires L, Hassan S. Chronic kidney disease and mortality in implantable cardioverter-defibrillator recipients. Cardiol Res Pract. 2010;2010:989261.
    1. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 1999;55:1553–1559. doi: 10.1046/j.1523-1755.1999.00391.x
    1. Perl J, Chan CT. Timing of sudden death relative to the hemodialysis procedure. Nat Clin Pract Nephrol. 2006;2:668–669. doi: 10.1038/ncpneph0345
    1. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488. doi: 10.1056/NEJMoa041489
    1. Korantzopoulos P, Liu T, Li L, Goudevenos JA, Li G. Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace. 2009;11:1469–1475. doi: 10.1093/europace/eup282
    1. Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation. 2002;105:1336–1341. doi: 10.1161/hc1102.100075
    1. Fernando M, Paterson HS, Byth K, Robinson BM, Wolfenden H, Gracey D, Harris D. Outcomes of cardiac surgery in chronic kidney disease. J Thorac Cardiovasc Surg. 2014;148:2167–2173. doi: 10.1016/j.jtcvs.2013.12.064
    1. Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, Pilgrim T, Petrinic T, Nikolakopoulou A, Salanti G, et al. . Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019;40:3143–3153. doi: 10.1093/eurheartj/ehz275
    1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, et al. ; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–1705. doi: 10.1056/NEJMoa1814052
    1. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, et al. ; Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–1715. doi: 10.1056/NEJMoa1816885
    1. Patel KK, Shah SY, Arrigain S, Jolly S, Schold JD, Navaneethan SD, Griffin BP, Nally JV, Desai MY. Characteristics and outcomes of patients with aortic stenosis and chronic kidney disease. J Am Heart Assoc. 2019;8:e009980. doi: 10.1161/JAHA.118.009980
    1. Makki N, Lilly SM. Advanced chronic kidney disease: relationship to outcomes post-TAVR, a meta-analysis. Clin Cardiol. 2018;41:1091–1096. doi: 10.1002/clc.22993
    1. Doshi R, Shlofmitz E, Shah J, Meraj P. Comparison of transcatheter mitral valve repair versus surgical mitral valve repair in patients with advanced kidney disease (from the National Inpatient Sample). Am J Cardiol. 2018;121:762–767. doi: 10.1016/j.amjcard.2017.12.015
    1. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, et al. ; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307–2318. doi: 10.1056/NEJMoa1806640
    1. Taramasso M, Pozzoli A, Guidotti A, Nietlispach F, Inderbitzin DT, Benussi S, Alfieri O, Maisano F. Percutaneous tricuspid valve therapies: the new frontier. Eur Heart J. 2017;38:639–647. doi: 10.1093/eurheartj/ehv766
    1. Shah B, Vemulapalli S, Manandhar P, Amoroso N, Ruiz-Maya T, Staniloae C, Saric M, Williams M. Comparison after transcatheter mitral valve repair in patients with chronic kidney disease: an analysis of 5,241 patients in the United States. J Am Coll Cardiol. 2018;71:A1980
    1. Carubelli V, Metra M, Lund LH. Negotiating renal dysfunction when treating patients with heart failure. Expert Rev Cardiovasc Ther. 2018;16:113–122. doi: 10.1080/14779072.2018.1422178
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. ; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720
    1. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. doi: 10.1056/NEJMoa1611925
    1. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. ; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357. doi: 10.1056/NEJMoa1812389
    1. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. ; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744
    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al. ; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. doi: 10.1056/NEJMoa2024816
    1. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, et al. ; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. doi: 10.1056/NEJMoa1911303
    1. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. ; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424. doi: 10.1056/NEJMoa2022190
    1. Lan NSR, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6:927–935. doi: 10.1002/ehf2.12505
    1. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–2117. doi: 10.1007/s00125-018-4670-7
    1. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453–2463. doi: 10.1093/eurheartj/eht187
    1. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, et al. ; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884–894. doi: 10.1001/jama.2015.10081

Source: PubMed

3
Se inscrever